NASDAQ:IONS

Ionis Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy IONS

*Your capital is at risk

$54.01

+0.620 (+1.16%)

At Close: Jul 22, 2026

Ionis Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -74.76. In total, the insiders bought 757.69K and sold 364.31K IONS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-74.76
● Buy	757.69K shares
● Sell	364.31K shares
73% Buy Activity Moderate Negative Correlation
Sell Signal High Confidence Jan 16, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -74.76. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 24, 2026 Buy	Common Stock M-Exempt	Monia Brett P Chief Executive Officer	CEO / President	14 565 Value: $474.8K
Jun 15, 2026 Buy	Non-Qualified Stock Option (right to buy) M-Exempt	Berthelsen Spencer R Director	Director	8 000 Value: $195.4K
Jun 15, 2026 Sell	Common Stock S-Sale	Berthelsen Spencer R Director	Director	8 000 Value: $587.9K
Jun 15, 2026 Buy	Common Stock M-Exempt	Berthelsen Spencer R Director	Director	8 000 Value: $195.4K
Jun 12, 2026 Buy	Common Stock M-Exempt	Kordasiewicz Holly B. EVP, Chief Development Officer	Officer	19 895 Value: $1.13M
Jun 12, 2026 Buy	Common Stock M-Exempt	Kordasiewicz Holly B. EVP, Chief Development Officer	Officer	12 000 Value: $391.2K
Jun 12, 2026 Buy	Common Stock M-Exempt	Kordasiewicz Holly B. EVP, Chief Development Officer	Officer	21 000 Value: $1.28M
Jun 12, 2026 Sell	Common Stock S-Sale	Kordasiewicz Holly B. EVP, Chief Development Officer	Officer	41 004 Value: $3.00M
Jun 12, 2026 Buy	Common Stock M-Exempt	Kordasiewicz Holly B. EVP, Chief Development Officer	Officer	7 951 Value: $484.1K
Jun 12, 2026 Buy	Non-Qualified Stock Option (right to buy) M-Exempt	Kordasiewicz Holly B. EVP, Chief Development Officer	Officer	21 000 Value: $1.28M
Jun 12, 2026 Buy	Non-Qualified Stock Option (right to buy) M-Exempt	Kordasiewicz Holly B. EVP, Chief Development Officer	Officer	19 895 Value: $1.13M
Jun 12, 2026 Buy	Non-Qualified Stock Option (right to buy) M-Exempt	Kordasiewicz Holly B. EVP, Chief Development Officer	Officer	12 000 Value: $391.2K
Jun 12, 2026 Buy	Non-Qualified Stock Option (right to buy) M-Exempt	Kordasiewicz Holly B. EVP, Chief Development Officer	Officer	7 951 Value: $484.1K
Jun 12, 2026 Sell	Common Stock S-Sale	Kordasiewicz Holly B. EVP, Chief Development Officer	Officer	19 842 Value: $1.47M
Jun 04, 2026 Buy	Non-Qualified Stock Option (right to buy) A-Award	Reikes Peter N Director	Director	10 753 Value: $807.9K
Jun 04, 2026 Buy	Non-Qualified Stock Option (right to buy) A-Award	Hantson Ludwig Director	Director	10 753 Value: $807.9K
Jun 04, 2026 Buy	Common Stock J-Other	Reikes Peter N	Director	0 Value: $0
Jun 04, 2026 Buy	Common Stock J-Other	Hantson Ludwig	Director	0 Value: $0
Jun 01, 2026 Sell	Common Stock S-Sale	Berthelsen Spencer R Director	Director	8 000 Value: $605.4K
Jun 01, 2026 Buy	Common Stock M-Exempt	Berthelsen Spencer R Director	Director	8 000 Value: $195.4K
Jun 01, 2026 Buy	Non-Qualified Stock Option (right to buy) M-Exempt	Berthelsen Spencer R Director	Director	8 000 Value: $195.4K
May 14, 2026 Buy	Common Stock M-Exempt	Monia Brett P Chief Executive Officer	CEO / President	3 220 Value: $105.0K
May 14, 2026 Sell	Common Stock S-Sale	Monia Brett P Chief Executive Officer	CEO / President	3 220 Value: $253.3K
May 14, 2026 Buy	Non-Qualified Stock Option (right to buy) M-Exempt	Monia Brett P Chief Executive Officer	CEO / President	3 220 Value: $105.0K
May 13, 2026 Buy	Common Stock M-Exempt	Monia Brett P Chief Executive Officer	CEO / President	1 316 Value: $42.9K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT IONIS PHARMACEUTICALS

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various...

Read Full Profile Here